Department of Pediatrics, Division of Stem Cell Transplantation, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.
Department of Biomedical Data Sciences, Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands.
Pediatr Blood Cancer. 2023 Nov;70(11):e30638. doi: 10.1002/pbc.30638. Epub 2023 Aug 28.
Survival rates have continued to increase for pediatric hematopoietic stem cell transplantation (HSCT) for nonmalignant diseases. Despite the crucial role of caregivers in this high-intensity treatment, knowledge about long-term parental impact is lacking.
This cross-sectional study assessed parental distress and everyday problems in parents of patients 2 years and older after pediatric HSCT for a nonmalignant disease using Distress Thermometer for Parents (DT-P), and compared outcomes to matched Dutch parents of healthy children and Dutch parents of children with a chronic condition (CC).
Median follow-up was 5.3 years (interquartile range [IQR]: 2.9-8.6). Underlying diseases were inborn errors of immunity (N = 30), hemoglobinopathies (N = 13), and bone marrow failure (N = 27). Mothers of pediatric HSCT recipients (N = 70) reported comparable overall distress levels to mothers of healthy children, but experienced more distress related to parenting problems, specifically managing their child's emotions, discussing disease consequences, and fostering independence. Fathers of HSCT recipients (N = 45) reported higher overall distress levels and had more emotional distress compared to fathers of healthy children.
Overall, parental distress and everyday problems of parents of HSCT recipients are comparable to those of parents of children with CC. However, there is ongoing parental burden, both emotional and in parenting, long-term after HSCT compared to parents of healthy children, and the type of burden differs between mothers and fathers. These results indicate that individualized parental supportive care should not remain restricted to the acute hospitalization phase, but also be actively offered during long-term follow-up after pediatric HSCT.
儿科造血干细胞移植(HSCT)治疗非恶性疾病的存活率持续提高。尽管照顾者在这种高强度治疗中起着至关重要的作用,但对长期父母影响的了解却很缺乏。
本横断面研究使用父母痛苦温度计(DT-P)评估了 2 岁及以上接受非恶性疾病儿科 HSCT 的患者的父母的痛苦和日常问题,并将结果与荷兰健康儿童的父母和患有慢性疾病(CC)的儿童的荷兰父母相比较。
中位随访时间为 5.3 年(四分位距[IQR]:2.9-8.6)。基础疾病为先天性免疫缺陷(N=30)、血红蛋白病(N=13)和骨髓衰竭(N=27)。儿科 HSCT 受者的母亲(N=70)报告的总体痛苦水平与健康儿童的母亲相当,但在育儿问题上经历了更多的痛苦,特别是在管理孩子的情绪、讨论疾病后果和培养独立性方面。HSCT 受者的父亲(N=45)报告的总体痛苦水平较高,与健康儿童的父亲相比,他们的情绪痛苦更多。
总体而言,HSCT 受者父母的痛苦和日常问题与 CC 儿童的父母相似。然而,与健康儿童的父母相比,HSCT 后长期存在持续的父母负担,包括情感和育儿方面的负担,而且母亲和父亲的负担类型不同。这些结果表明,个性化的父母支持性护理不应仅限于急性住院阶段,还应在儿科 HSCT 后长期随访中积极提供。